Modernizing the Functional Service Provider (FSP) Relationship: Innovations to bring value beyond “Global and Scalable”

[Fill out the form below to register]
Abstract: The Global Clinical Research Organization (CRO) market is expected to grow to $71.7 billion in 2024. Within that growth, Functional Service Provider (FSP) relationships are expected to grow at a CAGR of 5%-6%. Sponsor organizations turn to the FSP model as an outsourcing strategy for multiple reasons. Efficiency, consistency, scalability, global reach, and cost reduction generally top that list. CROs, in turn, have evolved their culture, resourcing, and infrastructure to best suit FSP relationships
Given the increasing reliance on global support models, virtual work teams, and the complexity and increasing amounts of data and advancements in technology – sponsor organizations need more from their FSP partners. The best-fit partners bring the functional line expertise plus an innovation mindset and tangible methods to identify, and where requested, help organizations to transform their way of operating.
Attendees will learn:
- How FSP partners can go beyond “Global and Scalable”
- How to bridge time zones and distance without compromising performance
- How to create and maintain a culture of alignment with customer goals, standards, and results
- Innovative methods for leading the charge to bring innovation and efficiencies
- Sample innovations that have transformed FSP partnership operating models
This webinar is intended for small to mid-size organizations – those utilizing the FSP model today and those considering implementing FSP relationships in the future.
Presenters:
Donnelle LaDouceur, Director, Functional Service Solutions
Jim Balcom, Director, Innovation and Automation
Diederik Van Niekerk, Senior Manager, South Africa Operations

Register for the webinar
Suggested For You

perspectives
February 13th, 2025
Helping European Drug Development Companies Succeed in the US Market

perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar

perspectives
September 30th, 2024
The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives
September 11th, 2024
From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

perspectives
July 30th, 2024
The Critical Role of Quality Control (QC) – Medical Writing and Beyond

perspectives
July 23rd, 2024
PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

perspectives
July 16th, 2024
Key Steps to Successful CMC Authoring of IND and IMPD Submissions

perspectives
July 9th, 2024
Managing RTOR Submissions: How to Run a Successful Race from the Top Line Starting Line

perspectives
July 2nd, 2024
Part 1: RWD Noninterventional Study Design and FDA Engagement Opportunity for Early Stage Oncology

perspectives
June 21st, 2024
Peer-Reviewed Journal Articles: The Crucial Role of Publication in the Pharmaceutical Industry

perspectives
June 14th, 2024
A Structured Approach to Benefit-Risk Assessment Throughout Product Development in the Pharmaceutical Industry

perspectives
June 6th, 2024
Datacise and Diversity in Patient Enrollment: Combining Geospatial and Demographic Data to Aid Site Selection